Risk factor
Very poor trading liquidity
Profitability factor
Greatly overvalued vs peers
About
PlexBio Co., Ltd. is dedicated to the creation and production of in vitro diagnostic (IVD) solutions for both molecular biology and immunology purposes. Their comprehensive product range features services for optimizing diagnostic workflows, as well as automated kits for sample preparation and extraction. A key innovation is their IntelliPlex platform, which leverages pCode technology to enable advanced, "sample-to-answer" multiplexing assays. The company also supplies specialized oncology panels designed for detecting lung cancer, gene mutations, and chromosomal rearrangements. Additionally, PlexBio offers a variety of infectious disease tests, including IntelliPlex kits for SARS-CoV-2 detection, influenza, and SARS-CoV-2 variant analysis, complemented by essential reagents such as pCode coupling buffer sets. Founded in 2009, PlexBio Co., Ltd. operates from its headquarters in Taipei, Taiwan.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.